Medtronic’s SPR Therapeutics deal signals a sharper move into earlier chronic pain intervention
Chronic pain care needs non-opioid options. Medtronic’s SPR Therapeutics deal tests whether temporary PNS can scale beyond niche adoption.
Why Donor Alliance and LifeSource are building a new model for transplant system performance
Organ donation needs trust and accountability. Vital Impact Health Group tests whether nonprofit OPO collaboration can raise transplant standards.
Is Avvio Medical building the next outpatient frontier in kidney stone and ureteral stone therapy?
Ureteral stones need faster care. Avvio Medical’s outpatient device tests whether microbubble lithotripsy can ease OR bottlenecks.
Artivion’s Endospan acquisition puts NEXUS at the centre of aortic arch device competition
Artivion now owns NEXUS. The bigger test is whether FDA approval can become a scalable U.S. aortic arch business.
HistoSonics just cleared a major Asia hurdle. Could histotripsy move beyond liver tumors next?
HistoSonics cleared Taiwan, but the bigger test is whether histotripsy can scale from liver tumors into broader oncology use.
Can Fujifilm’s EB-710US simplify lung cancer staging procedures in the United States?
EBUS imaging is clinically valuable, but workflow remains messy. Fujifilm’s EB-710US tests whether simpler design can change adoption.
Veracyte’s TrueMRD Medicare win pushes whole-genome MRD testing into bladder cancer surveillance
MRD testing is moving from research to reimbursement. Veracyte now has Medicare coverage, but adoption in bladder cancer care is the harder test.
Mevion’s European expansion gains momentum with Southern Italy proton therapy project
Proton therapy is precise but hard to scale. Mevion’s Naples win tests whether compact systems can shift access across Southern Europe.
What Natera’s Signatera CDx approval changes for adjuvant Tecentriq use in bladder cancer
MRD testing just crossed into treatment selection. Natera’s Signatera FDA win could reshape adjuvant bladder cancer care.
Genentech’s Tecentriq decision puts Natera’s Signatera at the centre of precision bladder cancer care
Bladder cancer treatment is becoming more selective. Tecentriq’s ctDNA-guided approval may redefine who gets adjuvant immunotherapy.